Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Executive Summary
As Egalet's Arymo ER heads to panel, agency tries to head off discussion about whether it should be approving new opioid products and whether longer clinical efficacy trials should be demanded.
You may also be interested in...
NIH Advisors Back Insuring Complementary, Alternative Solutions To Drugs For Health Care
Consumers with chronic pain spend less in co-pays for pain medications than they would for natural remedies or treatments such as chiropractic or acupuncture because few insurance plans pay for alternative care, NIH advisory committee members say.
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.